Artelo Biosciences Announces Proposed Underwritten Public Offering

Core Viewpoint - Artelo Biosciences, Inc. has announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants, aimed at raising capital for its clinical-stage pharmaceutical developments [1] Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions including cancer, pain, and dermatologic issues [1][6] - The company has a diversified pipeline addressing significant unmet medical needs in areas such as anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation [6] - Artelo is also implementing a digital asset treasury strategy, deploying excess capital into Solana [6] Offering Details - The offering is being managed by R.F. Lafferty & Co., Inc. as the sole book-running manager [2] - The shares are being offered under a "shelf" registration statement filed with the U.S. Securities and Exchange Commission (SEC) [2] - A prospectus supplement detailing the terms of the public offering will be filed with the SEC [3] Additional Information - Copies of the prospectus supplement and accompanying prospectus will be available on the SEC's website and from R.F. Lafferty & Co., Inc. [4] - The press release clarifies that it does not constitute an offer to sell or solicit offers to buy any of the securities described [5] - For investor relations, Crescendo Communications, LLC is the contact point [8]